Aerie Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($3.17) Per Share (AERI)
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) – Research analysts at Cantor Fitzgerald cut their FY2017 EPS estimates for Aerie Pharmaceuticals in a note issued to investors on Wednesday. Cantor Fitzgerald analyst E. Piros now anticipates that the company will earn ($3.17) per share for the year, down from their prior forecast of ($2.99). Cantor Fitzgerald has a “Overweight” rating and a $62.00 price target on the stock. Cantor Fitzgerald also issued estimates for Aerie Pharmaceuticals’ FY2018 earnings at ($2.17) EPS.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.02. TRADEMARK VIOLATION NOTICE: “Aerie Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($3.17) Per Share (AERI)” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://theolympiareport.com/2017/08/28/aerie-pharmaceuticals-inc-forecasted-to-earn-fy2017-earnings-of-3-17-per-share-aeri.html.
AERI has been the topic of a number of other research reports. Aegis increased their target price on Aerie Pharmaceuticals from $63.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, May 25th. HC Wainwright restated a “buy” rating and set a $69.00 price objective on shares of Aerie Pharmaceuticals in a research note on Thursday, May 25th. BidaskClub upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, July 24th. ValuEngine upgraded Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Cowen and Company set a $100.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, May 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Aerie Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $66.08.
Shares of Aerie Pharmaceuticals (NASDAQ AERI) opened at 53.50 on Monday. Aerie Pharmaceuticals has a 12 month low of $18.52 and a 12 month high of $59.50. The firm’s market cap is $1.94 billion. The firm has a 50-day moving average of $54.13 and a 200 day moving average of $48.67.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AERI. Goldman Sachs Group Inc. boosted its position in Aerie Pharmaceuticals by 28.5% in the first quarter. Goldman Sachs Group Inc. now owns 223,053 shares of the company’s stock worth $10,115,000 after buying an additional 49,473 shares in the last quarter. BlackRock Inc. raised its stake in Aerie Pharmaceuticals by 113,376.8% in the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock worth $117,951,000 after buying an additional 2,598,596 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in Aerie Pharmaceuticals by 5.8% in the first quarter. Parametric Portfolio Associates LLC now owns 68,398 shares of the company’s stock worth $3,102,000 after buying an additional 3,739 shares in the last quarter. Turner Investments LLC purchased a new stake in Aerie Pharmaceuticals during the first quarter worth $227,000. Finally, Vanguard Group Inc. raised its stake in Aerie Pharmaceuticals by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,392,525 shares of the company’s stock worth $63,151,000 after buying an additional 92,463 shares in the last quarter. 94.64% of the stock is currently owned by hedge funds and other institutional investors.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.